Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy - SL-3Q2A
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Acronyms SL-3Q2A
- Sponsors Roxall Medizin GmbH
Most Recent Events
- 08 Oct 2025 New trial record